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ARTICLE
Genotype-Phenotype Correlation in NF1: Evidence
for a More Severe Phenotype Associated with
Missense Mutations Affecting NF1 Codons 844–848
Magdalena Koczkowska,1 Yunjia Chen,1 Tom Callens,1 Alicia Gomes,1 Angela Sharp,1 Sherrell Johnson,1
Meng-Chang Hsiao,1 Zhenbin Chen,1 Meena Balasubramanian,2 Christopher P. Barnett,3
Troy A. Becker,4 Shay Ben-Shachar,5 Debora R. Bertola,6 Jaishri O. Blakeley,7
Emma M.M. Burkitt-Wright,8 Alison Callaway,9 Melissa Crenshaw,4 Karin S. Cunha,10
Mitch Cunningham,11 Maria D. D’Agostino,12 Karin Dahan,13 Alessandro De Luca,14 Anne Destrée,13
Radhika Dhamija,15 Marica Eoli,16 D. Gareth R. Evans,8 Patricia Galvin-Parton,17
Jaya K. George-Abraham,18 Karen W. Gripp,19 Jose Guevara-Campos,20 Neil A. Hanchard,21
Concepcion Hernández-Chico,22 LaDonna Immken,18 Sandra Janssens,23 Kristi J. Jones,24
(Author list continued on next page)

Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth incidence of 1:2,000–3,000, is characterized by a highly variable
clinical presentation. To date, only two clinically relevant intragenic genotype-phenotype correlations have been reported for NF1
missense mutations affecting p.Arg1809 and a single amino acid deletion p.Met922del. Both variants predispose to a distinct mild
NF1 phenotype with neither externally visible cutaneous/plexiform neurofibromas nor other tumors. Here, we report 162 individuals
(129 unrelated probands and 33 affected relatives) heterozygous for a constitutional missense mutation affecting one of five neighboring
NF1 codons—Leu844, Cys845, Ala846, Leu847, and Gly848—located in the cysteine-serine-rich domain (CSRD). Collectively, these
recurrent missense mutations affect 0.8% of unrelated NF1 mutation-positive probands in the University of Alabama at Birmingham
(UAB) cohort. Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were more prevalent in these individuals compared with classic NF1-affected cohorts (both p < 0.0001). Nearly half of the individuals had symptomatic or asymptomatic
optic pathway gliomas and/or skeletal abnormalities. Additionally, variants in this region seem to confer a high predisposition to
develop malignancies compared with the general NF1-affected population (p ¼ 0.0061). Our results demonstrate that these NF1
missense mutations, although located outside the GAP-related domain, may be an important risk factor for a severe presentation. A
genotype-phenotype correlation at the NF1 region 844–848 exists and will be valuable in the management and genetic counseling of
a significant number of individuals.

Introduction
Neurofibromatosis type 1 (NF1 [MIM: 162200]), one of the
most common genetic disorders with a birth incidence of 1
in 2,000–3,000,1–3 is characterized by a highly variable

inter- and intrafamilial expressivity (see GeneReviews in
Web Resources). It is caused by loss-of-function genetic
variants in NF1 (MIM: 613113), located on chromosome
17q11.2. NF1 encodes neurofibromin, a GTPase activating protein (GAP) that downregulates the RAS signal
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transduction pathway through its GAP-related domain
(GRD).4,5 The most common first signs of NF1 are multiple
café-au-lait macules (CALMs) in >95% of infants and skinfold freckling in >80% of children by the age of 7 years.6
Other clinical features observed in >90% of adults with
NF1 are iris Lisch nodules and cutaneous neurofibromas.7 Individuals with a more severe phenotype present with plexiform and/or spinal neurofibromas, symptomatic optic pathway gliomas (OPGs), as well as specific
osseous lesions, such as sphenoid wing or tibial dysplasia.
Approximately 50% of NF1-affected case subjects have
de novo mutations, while the remaining individuals inherit
the disorder from an affected parent (see GeneReviews in
Web Resources). According to the National Institutes of
Health (NIH) diagnostic criteria, at least two of the aforementioned features are required to classify a person as having the clinical diagnosis of NF1.8
Due to the variability in clinical presentation, age dependency of most manifestations, the timing and number of
second hits in specific cells, and the wide NF1 allelic heterogeneity, identification of specific genotype-phenotype
correlations is extremely challenging. To date, more than
2,800 different germline NF1 pathogenic variants have
been identified in the University of Alabama at Birmingham
(UAB) cohort, with only 31 unique pathogenic variants
present in R0.5% of all unrelated individuals (L.M.M.,
unpublished data). Moreover, a mild NF1 phenotype,
including only CALMs and skinfold freckles, overlaps with
Legius syndrome (MIM: 611431), caused by mutations in
SPRED1 (MIM: 609291).9,10
So far, only three clinically significant genotype-phenotype correlations have been reported. First, individuals
with a constitutional NF1 microdeletion usually show a

more severe phenotype compared to the general NF1affected population. The NF1 microdeletion syndrome
(MIM: 613675) is typically characterized by a large number
of neurofibromas at a young age, dysmorphic facial
features (hypertelorism, downslanted palpebral fissures,
broad nasal bridge, low-set ears, micrognathia, coarse
face, facial asymmetry), and developmental delay and/or
intellectual disability. Individuals may present with cardiac
defects as well as growth and skeletal abnormalities. NF1
microdeletions have been associated with an increased
lifetime risk for malignant peripheral nerve sheath tumors
(MPNSTs). The constitutional co-deletion of SUZ12
(MIM: 606245) within the common NF1-microdeletion
region is thought to be a risk factor for the malignant neoplasms.11 Second, individuals with a specific single amino
acid NF1 deletion (c.2970_2972del [p.Met992del]) present
with a milder phenotype. These individuals have multiple
CALMs with or without freckles, but no externally visible
cutaneous or plexiform neurofibromas.12 A third genotype-phenotype correlation involving NF1 missense mutations affecting arginine at position 1809 is also associated
with a distinct presentation,13,14 including developmental
delay and/or learning disabilities, pulmonic stenosis, and
Noonan-like features, but no external plexiform neurofibromas or symptomatic OPGs. Both of these affected
amino acids reside outside the GRD domain.
Another distinct form of NF1 is familial spinal neurofibromatosis (FSNF [MIM: 162210]) originally described by
Pulst et al.15 in six affected members from two unrelated
families. It is characterized by bilateral and histologically
proven neurofibromas of all spinal dorsal roots with a
paucity or absolute lack of cutaneous manifestations.16,17
So far, only 100 individuals (both familial and sporadic)
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Padova 35128, Italy; 41Department of Neurology, Boston Children’s Hospital, Boston, MA 02115, USA; 42Division of Cancer and Genetics, Cardiff University, Cardiff CF14 4XN, UK; 43Department of Clinical Genetics, Erasmus Medical Center, Rotterdam 3015 GE, the Netherlands; 44Department of Paediatrics,
Division of Paediatric Neurology, Ghent University Hospital, Ghent 9000, Belgium; 45Department of Molecular Genetics & Microbiology, University of
Florida College of Medicine, Gainesville, FL 32610, USA; 46Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore;
47
Faculty of Health Sciences, School of Medicine, University of Adelaide, Adelaide, SA 5000, Australia; 48Department of Molecular and Medical Genetics,
Oregon Health and Science University, Portland, OR 97239, USA; 49Department of Human Genetics, KU Leuven - University of Leuven, Leuven 3000,
Belgium
50
All editorial responsibility for this paper was handled by an associate editor of The Journal
*Correspondence: lmessiaen@uabmc.edu
https://doi.org/10.1016/j.ajhg.2017.12.001.

70 The American Journal of Human Genetics 102, 69–87, January 4, 2018

have been reported with this form.17 It has been suggested
that individuals with the severe subtype of FSNF
more frequently carry an NF1 missense or splicing
mutation.18–20 Of particular interest are two families: a
two-generation family with three first-degree relatives
reported by Pascual-Castroviejo et al.21 and a three-generation family with three first-degree relatives reported by
Burkitt-Wright et al.16 Specific NF1 missense mutations
c.2542G>C (p.Gly848Arg) and c.2543G>A (p.Gly848Glu),
located in the cysteine-serine-rich domain (CSRD), were
present in all individuals affected by multiple spinal dorsal
root neurofibromas. Despite the evidence that c.2542G>C
(p.Gly848Arg) is a clearly pathogenic mutation, two
recent studies using mouse models did not recapitulate
the phenotype identified in humans.22,23 Genetically
engineered mice with c.2542G>C (p.Gly848Arg) mutation
developed neither OPGs nor plexiform neurofibromas,
demonstrating phenotypic divergence between NF1affected individuals and mice.22,23
In this study, we report a cohort of 129 unrelated
probands and 33 affected relatives heterozygous for a
constitutional missense mutation affecting one of five
neighboring NF1 codons—Leu844, Cys845, Ala846,
Leu847, and Gly848. These individuals have a high prevalence of a severe phenotype, including plexiform and
symptomatic spinal neurofibromas, symptomatic optic
pathway gliomas, other malignant neoplasms, and bone
abnormalities. The current findings clearly demonstrate
that missense mutations outside the GRD are not solely
associated with a mild phenotype.

Material and Methods
Individuals and Phenotypic Data
A total of 162 individuals heterozygous for a missense mutation
affecting one of five neighboring NF1 codons (Leu844, Cys845,
Ala846, Leu847, and Gly848) were included in the study. Blood
samples from 78 individuals (67 probands and 11 relatives) were
originally sent to the UAB Medical Genomics Laboratory for
molecular NF1 genetic testing to establish or confirm the diagnosis
for NF1. This initial study was expanded to include an additional
84 individuals (62 probands and 22 relatives), molecularly diagnosed in collaborating institutions (as detailed in Table S1).
All individuals included in this study were clinically assessed
using the standardized phenotypic checklist form as previously
reported (Figure S1).14 The clinical data were collected at the
time of mutation analysis and re-verified for accuracy by referring physicians co-authoring this paper at the time of this study.
Additionally, referring physicians updated the phenotypic data
at the time of this genotype-phenotype study, when available,
i.e., when the individual had been seen and followed at their
institution after genetic testing results were reported. The phenotypic data and age provided correspond to the latest clinical
evaluation. The phenotypic checklist form consists of two parts:
(1) general information including gender, date of birth,
ethnicity, height, head circumference (HC), weight, fulfillment
of the NIH diagnostic criteria, and mode of inheritance and
(2) NF1 signs and symptoms, including CALMs, skinfold freck-

ling, Lisch nodules, cutaneous and subcutaneous, plexiform
and spinal neurofibromas, OPGs and other neoplasms, skeletal
and cardiac abnormalities, development and education levels,
presence/absence of Noonan syndrome features, and segmental
phenotype.
Fifteen major clinical features of NF1 were selected for the
genotype-phenotype correlation study (Tables 1, 2, and 3). Individuals with missing data for a particular sign and/or symptom
were classified as ‘‘unknown’’ or ‘‘not specified’’ and consequently
excluded from that part of the genotype-phenotype analysis. Most
features were identified by physical examination; ophthalmologic
examination for Lisch nodules and imaging to detect asymptomatic OPGs and spinal neurofibromas was not performed in most
individuals. Brain and spine/whole-body MRI was done mainly
in individuals with signs and/or symptoms indicative of OPGs
or internal/spinal neurofibromas; however, depending on institutional policies, some individuals were screened by MRI despite the
absence of symptoms. Noonan phenotype was diagnosed if at
least two of the following features were observed: short stature,
hypertelorism, low-set ears, webbed neck, ptosis, midface hypoplasia, or pulmonic stenosis. To evaluate short stature and macrocephaly, the World Health Organization (WHO) and the Center
for Disease Control (CDC) growth charts and the Gerhard
Nellhaus’ curve24 were used as previously described.14 Short
stature and macrocephaly were defined as height below or equal
to the 3rd percentile (PC % 3) and as head circumference equal
or above the 98th percentile (PC R 98), respectively. For cognitive
impairment/learning disabilities, individuals with attention
deficit disorder (ADD) and/or attention deficit hyperactivity disorder (ADHD) but normal development were classified as normal.
To establish a genotype-phenotype association, we used the
same approach as previously described.14 We compared the phenotypes of individuals with missense mutations affecting codons
844–848 with the cohort of 169 individuals with missense mutations affecting p.Arg1809,13,14,25–27 47 individuals heterozygous
for c.2970_2972del (p.Met992del) mutations,12 and previously
described large-scale NF1-affected individual cohorts with
‘‘classic’’ NF1.7,28–40
This study was approved by the Institutional Review Boards of
all participating institutions offering clinical genetic testing.

Molecular Analysis
In the Medical Genomics Laboratory at UAB, comprehensive
NF1 mutation screening using an RNA-based approach complemented by DNA-dosage analysis was performed as previously
described.41,42 The status of the specific familial mutation in
relatives was ascertained by bidirectional Sanger sequencing
(ABI PRISM 3730, Life Technologies).
The nomenclature of the mutations is based on NF1 mRNA
sequence GenBank: NM_000267.3 according to the recommendations of the Human Genome Variation Society (HGVS). For exon
numbering we used the NCBI numbering, followed by the historical numbering in square brackets originally developed by the NF1
community.42

In Silico Prediction of Effect of Missense Mutations
Eight software programs were used to predict the effects of
missense variants: two online in silico prediction tools (CADD
v.1.3 and PolyPhen-2) and six complementary tools (Grantham
Difference, SIFT v.4.0.3, SpliceSiteFinder-like, MaxEntScan,
NNSplice v.0.9, and Human Splicing Finder v.2.4.1) embedded
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Table 1.

Demographic and Clinical Characterization of Individuals with a Missense Mutation Affecting Codons 844–848
Codon 844

Codon 845

Codon 846

Codon 847

Codon 848

All Codons 844–848
162 [129:33]

c.2530C>T
(p.Leu844Phe)
[10:1]; c.2531T>A
(p.Leu844His) [2:0];
c.2531T>C
(p.Leu844Pro)
[7:0]; c.2531T>G
(p.Leu844Arg) [6:0]

c.2533T>C
(p.Cys845Arg)
[3:1]; c.2534G>A
(p.Cys845Tyr) [8:0]

c.2536G>C
(p.Ala846Pro)
[1:2]; c.2537C>A
(p.Ala846Asp) [5:2]

c.2540T>C
(p.Leu847Pro)
[58:12]; c.2540T>G
(p.Leu847Arg) [8:0]

c.2542G>A
(p.Gly848Arg)
[6:0]; c.2542G>C
(p.Gly848Arg)
[8:11]; c.2543G>A
(p.Gly848Glu) [7:4]

Mutation-positive
individuals
[Proband:Relative]

26 [25:1]

12 [11:1]

10 [6:4]

78 [66:12]

36 [21:15]

Age group, years

%8

9–18

R19

%8

9–18

R19

%8

9–18

R19

%8

9–18

R19

%8

9–18

R19

%8

9–18

R19

all ages

Total

12

5

9

4

2

6

3

1

6

28

14

36

13

5

18

60

27

75

162

Mutation
[Proband:Relative]

Total

Proband:Relative

12:0

5:0

8:1

4:0

2:0

5:1

2:1

1:0

3:3

27:1

12:2

27:9

6:7

4:1

11:7

51:9

24:3

54:21

129:33

Age range, years

1–8

9–16

24–55

1–2

15–16

19–48

4–5

18

33–69

1–8

9–18

19–72

1–7

10–17

19–74

1–8

9–18

19–74

1–74

Male: Female

6:6

4:1

1:8

1:3

1:1

1:5

2:1

0:1

1:5

10:18

5:9

19:17

9:4

2:3

5:13

28:32

12:15

27:48

67:95

Fulfilling the NIH criteria
if the family history is
taken into account

10/11

4/5

9/9

2/4

1/2

4/5

3/3

1/1

6/6

17/28

14/14

35/36

4/11

4/5

17/18

36/57

24/27

71/74

131/158

Fulfilling the NIH criteria
if solely taking the physical
signs into account

10/11

4/5

9/9

2/4

1/2

4/5

2/3

1/1

6/6

17/28

14/14

33/36

4/11

4/5

13/18

35/57

24/27

65/74

124/158

>5 CALMs

12/12

5/5

8/8

4/4

1/2

4/5

3/3

1/1

4/6

27/28

14/14

32/35

5/11

3/5

7/18

51/58

24/27

55/72

130/157

Freckling

10/10

4/5

6/7

0/4

1/2

4/5

2/2

1/1

5/5

12/23

13/13

31/34

4/10

3/5

8/18

28/49

22/26

54/69

104/144

2/9

1/4

4/4

0/1

0/0

1/2

0/1

0/1

2/2

4/19

3/9

17/19

2/8

0/5

6/14

8/38

4/19

30/41

42/98

2/11

2/5

5/9

2/4

1/2

2/4

0/2

0/1

0/5

3/25

3/14

17/28

3/11

3/5

5/18

10/53

9/27

29/64

48/144

Lisch nodules
Skeletal abnormalities

a

Plexiform neurofibromas

0/11

2/5

3/9

0/3

2/2

2/5

0/2

1/1

1/2

6/24

3/13

19/33

0/11

1/5

7/17

6/51

9/26

32/66

47/143

Cutaneous neurofibromasb

1/11

1/5

7/9

0/4

0/2

3/4

0/2

1/1

4/5

1/26

4/14

28/33

1/11

1/5

5/18

3/54

7/27

47/69

57/150

Subcutaneous
neurofibromasb

1/9

0/5

6/8

1/4

0/2

1/4

0/2

0/0

3/5

1/26

4/13

17/30

1/11

0/5

6/18

4/52

4/25

33/65

41/142

Cutaneous and
subcutaneousb

0/9

0/5

5/8

0/4

0/2

1/3

0/2

0/0

3/5

0/25

1/13

17/30

0/11

0/5

4/18

0/51

1/25

30/64

31/140

Symptomatic spinal
neurofibromas

0/10

0/3

0/8

0/2

1/2

0/4

0/2

0/0

0/2

1/23

1/13

2/27

0/11

1/4

7/16

1/48

3/22

9/57

13/127

Spinal neurofibromas
by MRIc

0/1

0/0

0/5

0/0

1/2

1/1

0/1

0/0

0/1

1/5

2/6

3/16

0/1

2/3

10/11

1/8

5/11

14/34

20/53

(Continued on next page)

Table 1.

Continued
Codon 844

Mutation
[Proband:Relative]
d

Codon 845

Codon 846

Codon 847

Codon 848

c.2530C>T
(p.Leu844Phe)
[10:1]; c.2531T>A
(p.Leu844His) [2:0];
c.2531T>C
(p.Leu844Pro)
[7:0]; c.2531T>G
(p.Leu844Arg) [6:0]

c.2533T>C
(p.Cys845Arg)
[3:1]; c.2534G>A
(p.Cys845Tyr) [8:0]

c.2536G>C
(p.Ala846Pro)
[1:2]; c.2537C>A
(p.Ala846Asp) [5:2]

c.2540T>C
(p.Leu847Pro)
[58:12]; c.2540T>G
(p.Leu847Arg) [8:0]

c.2542G>A
(p.Gly848Arg)
[6:0]; c.2542G>C
(p.Gly848Arg)
[8:11]; c.2543G>A
(p.Gly848Glu) [7:4]

All Codons 844–848

Total

1/11

1/5

0/9

0/3

0/2

0/5

1/3

1/1

0/3

2/25

1/13

2/27

1/11

1/5

1/13

5/53

4/26

3/57

12/136

Asymptomatic OPGse

2/6

1/2

2/4

0/1

0/2

0/2

0/1

0/0

0/3

1/8

6/9

4/13

1/4

0/2

1/6

4/20

7/15

7/28

18/63

Other neoplasmsf

1/11

0/4

1/8

0/2

0/1

0/4

0/2

0/1

0/3

1/24

3/14

11/34

2/11

1/5

1/15

4/50

4/25

13/64

21/139

Cognitive impairment
and/or learning disabilities

3/11

3/4

0/6

1/4

0/2

3/4

3/3

0/1

1/5

10/26

7/13

12/26

5/11

5/5

3/17

22/55

15/25

19/58

56/138

Noonan syndrome features

0/9

1/5

1/8

0/2

1/1

0/4

0/2

0/1

0/4

3/27

0/13

3/26

1/10

0/5

0/17

4/50

2/25

4/59

10/134

g

1/7

0/2

0/4

0/3

1/1

0/1

0/2

0/0

1/2

0/11

3/10

4/21

3/10

0/3

2/14

4/33

4/16

7/42

15/91

Macrocephaly

2/11

1/4

1/2

1/3

0/1

0/0

2/2

0/0

0/2

8/21

2/11

10/17

3/11

1/4

5/9

16/48

4/20

16/30

36/98

Pulmonic stenosis

0/8

1/5

0/6

0/2

0/2

1/1

0/3

0/0

0/5

0/23

0/13

0/20

0/8

0/3

0/14

0/44

1/23

1/46

2/113

Symptomatic OPGs
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Short stature

a
All bone abnormalities included, i.e., scoliosis (n ¼ 27), pectus excavatum (n ¼ 4), pectus carinatum (n ¼ 6), long bone dysplasia (n ¼ 4), pseudarthrosis (n ¼ 2), bone cysts (n ¼ 2), sphenoid wing dysplasia (n ¼ 2), ulnar
aplasia, dural ectasia, 4th lumbar vertebrae fragmentation, bowed long bones, tibial dysplasia, clinodactyly, postaxial polydactyly, and cherubism.
b
At least two cutaneous/subcutaneous neurofibromas were required to be considered as ‘‘positive for the criterion of neurofibromas.’’
c
The frequency of both symptomatic and asymptomatic spinal neurofibromas in individuals who had done MRI examination.
d
The presence or absence of symptomatic OPGs was determined by ophthalmological examination and confirmed by MRI.
e
Including only individuals without signs of symptomatic OPGs who underwent MRI examination.
f
Including benign and malignant neoplasms, except for OPGs and neurofibromas.
g
As no specific growth curves are available for the Hispanic and Asian populations, Hispanic and Asian individuals were excluded as having short or normal stature.
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Table 2.

Frequency of Clinical Features in Cohorts of Individuals with a Missense Mutation Affecting Leu844, Cys845, Ala846, Leu847, and Gly848
Number of Individuals (%) [95% Confidence Interval]

NF1 Feature
>5 CALMs
Skinfold freckling

a

Lisch nodules
Plexiform neurofibromasa
Cutaneous neurofibromas

b

Subcutaneous neurofibromas

b

Symptomatic spinal neurofibromas

a

a,c

Leu844

Cys845

Ala846

Leu847

Gly848

25/25 (100) [86.7–100]

9/11 (81.8) [52.3–94.9]

8/10 (80) [49–94.3]

73/77 (94.8) [87.4–98]

15/34 (44.1) [28.9–60.6]

10/12 (83.3) [55.2–95.3]

5/7 (71.4) [35.9–91.8]

6/6 (100) [61–100]

44/47 (93.6) [82.8–97.8]

11/23 (47.8) [29.2–67]

7/17 (41.2) [21.6–64]

1/3 (33.3) [6.2–79.2]

2/4 (50) [15–85]

24/47 (51.1) [37.2–64.7]

8/27 (29.6) [15.9–48.5]

5/14 (35.7) [16.3–61.2]

4/7 (57.1) [25–84.2]

2/3 (66.7) [20.8–93.9]

22/46 (47.8) [34.1–61.9]

8/22 (36.4) [19.7–57]

7/9 (77.8) [45.3–93.7]

3/4 (75) [30.1–95.4]

4/5 (80) [37.6–96.4]

28/33 (84.9) [69.1–93.4]

5/18 (27.8) [12.5–50.9]

6/8 (75) [40.9–92.9]

1/4 (25) [4.6–69.9]

3/5 (60) [23.1–88.2]

17/30 (56.7) [39.2–72.6]

6/18 (33.3) [16.3–56.3]

0/11 (0) [0–25.9]

1/6 (16.7) [3–56.4]

0/2 (0) [0–65.8]

3/40 (7.5) [2.6–19.9]

8/20 (40) [21.9–61.3]

0/5 (0) [0–43.5]

2/3 (66.7) [20.8–93.9]

0/1 (0) [0–79.4]

5/22 (22.7) [10.1–43.4]

12/14 (85.7) [60.1–96]

Symptomatic OPGs, age R5 yearsd

1/21 (4.8) [0.9–22.7]

0/7 (0) [0–35.4]

2/5 (40) [11.8–76.9]

5/47 (10.6) [4.6–22.6]

3/24 (12.5) [4.3–31]

Asymptomatic OPGs, age R5 yearse

4/10 (40) [16.8–68.7]

0/4 (0) [0–49]

0/3 (0) [0–56.2]

11/25 (44) [26.7–62.9]

1/10 (10) [1.8–40.4]

2/23 (8.7) [2.4–26.8]

0/7 (0) [0–35.4]

0/6 (0) [0–39]

15/72 (20.8) [13.1–31.6]

4/31 (12.9) [5.1–28.9]

Skeletal abnormalities

9/25 (36) [20.3–55.5]

5/10 (50) [23.7–76.3]

0/8 (0) [0–32.4]

23/67 (34.3) [24.1–46.3]

11/34 (32.4) [19.1–49.2]

Noonan syndrome features

2/22 (9.1) [2.5–27.8]

1/7 (14.3) [2.6–51.3]

0/7 (0) [0–35.4]

6/66 (9.1) [4.2–18.5]

1/32 (3.1) [0.6–15.8]

Spinal neurofibromas by MRI

Other neoplasms

f

Pulmonic stenosis

1/19 (5.3) [0.9–24.6]

1/5 (20) [3.6–62.5]

0/8 (0) [0–32.4]

0/56 (0) [0–6.4]

0/25 (0) [0–13.3]

Short statureg

1/13 (7.7) [13.7–33.3]

1/5 (20) [3.6–62.5]

1/4 (25) [4.6–69.9]

7/42 (16.7) [8.3–30.6]

5/27 (18.5) [8.2–36.7]

Macrocephaly

4/17 (23.5) [9.6–47.3]

1/4 (25) [4.6–69.9]

2/4 (50) [15–85]

20/49 (40.8) [28.2–54.8]

9/24 (37.5) [21.2–57.3]

Cognitive impairment and/or learning
disabilities

6/21 (28.6) [13.8–50]

4/10 (40) [16.8–68.7]

4/9 (44.4) [18.9–73.3]

29/65 (44.6) [33.2–56.7]

13/33 (39.4) [24.7–56.3]

Severe phenotype, age R19 yearsh

7/9 (77.8) [45.3–93.7]

4/6 (66.7) [30–90.3]

1/6 (16.7) [3–56.4]i

32/36 (88.9) [74.7–95.6]

12/18 (66.7) [43.8–83.7]

In individuals R9 years.
In individuals R19 years.
c
The frequency of both symptomatic and asymptomatic spinal neurofibromas in individuals who had undergone MRI examination.
d
The presence or absence of symptomatic OPGs was determined by ophthalmological examination and confirmed by MRI.
e
Including only individuals without signs of symptomatic OPGs who underwent MRI examination.
f
Including benign and malignant neoplasms, except for OPG and neurofibromas.
g
As no specific growth curves are available for the Hispanic and Asian populations, Hispanic and Asian individuals were excluded as having short or normal stature.
h
Individual was classified as having a severe phenotype if at least one of the following features was observed: plexiform and/or symptomatic spinal neurofibroma, symptomatic OPG, malignant neoplasm, or osseous lesions.
i
Among individuals with a missense mutation affecting codon 846, the status of plexiform and spinal neurofibromas was known only for 2/6 individuals (UG-R0781-S and UG-R665-F), thus a severe phenotype cannot be
excluded in the remaining four individuals with missing data.
a

b

Table 3. Comparison of Clinical Features of the Studied Group with the NF1 Arg1809 Cohort, the NF1 Met992del Cohort, and Large-Scale
Previously Reported Cohorts of Individuals with ‘‘Classic’’ NF1
Number of Individuals (%)

a

NF1 Feature

aa 844–848

Arg1809

>5 CALMs

130/157 (82.8)

157/169 (92.9)

Skinfold freckling
Lisch nodules

104/144 (72.2)
42/98 (42.9)

95/161 (59)
12/120 (10)

p Value (2-Tailed Fisher’s Exact Test)

Met992del

b

46/47 (97.9)
32/47 (68.1)
3/38 (7.9)

Previously
Reported
NF1 Cohorts
1,537/1,728 (89)c
1,403/1,667 (84.2)
729/1,237 (58.9)

c

c

e,f

aa 844–848
versus
Arg1809

aa 844–848
versus
Met992del

aa 844–848
versus
‘‘Classic’’ NF1

0.0060* ➘

0.0067* ➘

0.0263 ➘

0.0164 ➚

0.0007** ➘

<0.0001** ➚

<0.0001** ➚

0.0028* ➘

<0.0001** ➚

<0.0001** ➚

<0.0001** ➚

<0.0001** ➚

<0.0001** ➘

Major external
plexiform
neurofibromasd

36/92 (39.1)

0/105 (0)

0/41 (0)

120/648 (18.5)

Cutaneous
neurofibromasg

47/69 (68.1)

0/57 (0)

0/18 (0)

656/723 (90.7)f,h,i,j

<0.0001** ➚

Subcutaneous
neurofibromasg

33/65 (50.8)

0-5/57 (0-8.8)k

ND

297/515 (57.7)f,i,j

<0.0001** ➚

Symptomatic spinal
neurofibromasd,l

12/79 (15.2)
13/127 (10.2)

0/40 (0)
0/76 (0)

1/41 (2.4)
1/47 (2.1)

2/119 (1.7)e
36/2,058 (1.8)e,f,m

0.0080* ➚
0.0022* ➚

0.0341 ➚

0.0004** ➚
<0.0001** ➚

Symptomatic OPGs,
age R 5 yearsl,n

11/104 (10.6)
12/136 (8.8)

0/114 (0)
0/139 (0)

0/46 (0)
0/47 (0)

7/180 (3.9)e,o
64/1,650 (3.9)c

0.0002** ➚
0.0002** ➚

0.0186 ➚
0.0384 ➚

0.0404 ➚
0.0125* ➚

Asymptomatic OPGs,
age R 5 yearsl,p

16/52 (30.8)
18/63 (28.6)

0/35 (0)
0/38 (0)

ND

2/45 (4.4)o
70/519 (13.5)q,r,s

0.0001** ➚
<0.0001** ➚

Other malignant
neoplasmst

13/139 (9.4)

2/155 (1.3)u

0/47 (0)

18/523 (3.4)f

0.0023* ➚

0.0409 ➚

0.0061* ➚

Skeletal abnormalitiesd,l

38/91 (41.8)
48/144 (33.3)

14/72 (19.4)
21/126 (16.7)

8/41 (19.5)
9/47 (19.2)

14/96 (14.6)e
144/948 (15.2)e,f,j,v

0.0025* ➚
0.0020* ➚

0.0174 ➚

<0.0001** ➚
<0.0001** ➚

Scoliosisg

20/64 (31.3)

6/48 (12.5)

2/18 (11.1)

51/236 (21.6)h,j

0.0241 ➚

c

Noonan syndrome
features

10/134 (7.5)

46/148 (31.1)

4
(all from 1 family)

57/1,683 (3.4)

Pulmonic stenosis

2/113 (1.8)

14/132 (10.6)

4/47 (8.5)

25/2,322 (1.1)w

Short stature
Macrocephaly
Cognitive impairment
and/or learning
disabilities

15/91 (16.5)
36/98 (36.7)
56/138 (40.6)

32/111 (28.8)
31/107 (29)
80/159 (50.3)

5/47 (10.6)
4/45 (8.9)
8/47 (17)

0.0012** ➚
0.0043* ➚

<0.0001** ➘

0.0276 ➚

0.0076* ➘
0.0451 ➘

109/684 (15.9)

e,i

239/704 (33.9)

e,i

0.0005** ➚

190/424 (44.8)

e,f

0.0042* ➚

Statistically significant p values with false discovery rates of 0.05 (indicated by *) and 0.01 (indicated by **) after correction for multiple testing using BenjaminiHochberg procedure (see details in Table S10). After applying the Benjamini-Hochberg correction, p % 0.0125 remained statistically significant at FDR of 0.05,
while p values % 0.0012 were still be considered as significantly different at FDR of 0.01. The black arrows indicate the statistically significant differences of the NF1
clinical features prevalence between the studied group and the cohort(s) used for the comparison, with the up and down arrows representing an increase and a
decrease of the prevalence in the studied group, respectively. Abbreviation: ND, no data
a
Based on data from Pinna et al.,13 Rojnueangnit et al.,14 Nyström et al.,25 Ekvall et al.,26 and Santoro et al.27
b
Based on data from Upadhyaya et al.12
c
Previous NF1 cohort used for comparison: Friedman and Birch.32
d
In individuals R9 years in this study and Arg1809, R10 years in Met992del and other studies.
e
Previous NF1 cohort used for comparison: Huson et al.7
f
Previous NF1 cohort used for comparison: McGaughran et al.34
g
In individuals R19 years in this study and Arg1809, R20 years in Met992del and other studies.
h
Previous NF1 cohort used for comparison: Huson et al.28,29
i
Previous NF1 cohort used for comparison: Khosrotehrani et al.38
j
Previous NF1 cohort used for comparison: Plotkin et al.39
k
Five individuals with few (1–6) small, subcutaneous ‘‘possible’’ neurofibromas, none were biopsied and therefore none have been histologically confirmed.14
l
Second value is the frequency of a particular feature regardless of the individuals’ age.
m
Previous NF1 cohort used for comparison: Thakkar et al.35
n
The presence or absence of symptomatic OPGs was determined by ophthalmological examination and confirmed by MRI.
o
Previous NF1 cohort used for comparison: Van Es et al.31
p
Including only individuals without signs of symptomatic OPGs who underwent MRI examination.
q
Previous NF1 cohort used for comparison: Listernick et al.30
r
Previous NF1 cohort used for comparison: Blazo et al.37
s
Previous NF1 cohort used for comparison: Blanchard et al.40
t
Only malignant neoplasms, hence excluding neurofibromas and OPGs, have been taken into account.
u
Breast cancer (n ¼ 1) and Ewing sarcoma (n ¼ 1) were found in the NF1 Arg1809 cohort, no follow-up information on these individuals was available.14
v
Previous NF1 cohort used for comparison: Cnossen et al.33
w
Previous NF1 cohort used for comparison: Lin et al.36
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in Alamut visual software v.2.9.0 (Interactive Biosoftware). The
presence or absence of the variants was checked in population databases, including the Genome Aggregation Database (gnomAD),
1000 Genomes, and the Exome Variant Server (EVS) as well as in
disease databases: the Leiden Open Variation Database (LOVD),
ClinVar, and the Human Gene Mutation Database (HGMD) (last
accessed May 2017). Evolutionary conservation for human neurofibromin GenBank: NP_000258.1 residues 804–950 was evaluated
using Clustal software v.2.0.12. The palindromic sequences and
quadruplex forming G-Rich sequences (QGRS) were identified by
Palindrome search and QGRS Mapper, respectively.
Interpretation of variant pathogenicity was performed based on
the American College of Medical Genetics and Genomics (ACMG)
recommendations.43

Statistical Analysis
For univariate analysis, two-tailed Fisher’s exact test was used to
compare categorical variables with a p value < 0.05 considered
as statistically significant. The resulting p values were adjusted
for multiple comparisons using Benjamini-Hochberg (B-H)
procedure with false discovery rates (FDRs) of 0.05 and 0.01. The
95% confidence interval (CI) was also calculated when appropriate. All statistical analyses were performed with GraphPad
and VassarStats softwares.

Results
Description of Missense Mutations Affecting Codons
844–848
Exon 21 [16] is the largest NF1 exon (441 nucleotides), and
in it we identified, besides the missense variants affecting
the codons 844–848, a total of 19 different missense variants in 35 unrelated individuals from the UAB cohort.
Fourteen of these alterations were classified as variants of
uncertain significance (8/19) or likely benign (6/19) and
reported 1–3 times in the UAB cohort (Figure S2). Only
five variants were classified as pathogenic (4/19) or likely
pathogenic (1/19) according to the current recommendations.43 Region 844–848 in exon 21 [16] stood out due to
its high frequency of variants compared with the neighboring codons, indicating functional importance (Figures
S2 and S3). A similar distribution and spectrum of missense
alterations in the NF1 exon 21 [16] was observed in
the publicly available databases (ClinVar, LOVD, and
HGMD). Besides a clear cluster of recurrent variants in
codons 844–848, other alterations spread over the entire
exon 21 [16] were mostly classified as variants of uncertain
significance and reported 1–2 times in these databases
(Figure S2). The frequency of this cluster of variants in aa
844–848 is 0.8% (67/8,400) in unrelated NF1 mutationpositive individuals from the UAB cohort, second only to
the p.Arg1809 (1.2%), and therefore represents a significant hotspot for missense mutations within NF1.
In the 129 unrelated individuals reported here, we
identified 12 different NF1 missense alterations affecting
one of five neighboring codons in exon 21 [16] (Table 1
and Figure 1). Within the group of individuals with
p.Gly848Arg, two different substitutions were observed:

c.2542G>A (6/14) and c.2542G>C (8/14). Detailed characteristics of the identified missense mutations are shown in
Tables S2–S4 and Figure 1. All variants identified in this
study with confirmed origin of the variant were
submitted to the LOVD and ClinVar databases. Based
on the data accumulated in this report (Tables S1
and S2), these variants can all be classified as pathogenic
(Table S4) according to current recommendations.43
Among the aforementioned variants, 8/12 were present
in the LOVD database with 5/8 classified as pathogenic
(c.2533T>C [p.Cys845Arg], c.2536G>C [p.Ala846Pro],
c.2537C>A [p.Ala846Asp], c.2540T>C [p.Leu847Pro], and
c.2543G>A [p.Gly848Glu]) and 3/8 as variants of uncertain
significance (c.2534G>A [p.Cys845Tyr], c.2540T>G
[p.Leu847Arg], and c.2542G>C [p.Gly848Arg]). Eight of
the 12 were present in ClinVar, including 3/8 classified as
pathogenic (c.2531T>G [p.Leu844Arg], c.2540T>C
[p.Leu847Pro], and c.2542G>C [p.Gly848Arg]), 1/8 as likely
pathogenic (c.2534G>A [p.Cys845Tyr]), 1/8 as a variant of
uncertain significance (c.2533T>C [p.Cys845Arg]), and 3/5
with no significance provided (c.2530C>T [p.Leu844Phe],
c.2531T>C [p.Leu844Pro], and c.2543G>A [p.Gly848Glu])
(Tables S2 and S3). One individual (UAB-R4444)
with c.2531T>A (p.Leu844His) carried another novel
alteration (c.2524G>A); assuming both variants reside
in cis, this alteration should be described as c.2524_2531
delinsAGCTTCCA
(p.Gly842_Leu844delinsSerPheHis).
None of these variants, except for c.2531T>G
(p.Leu844Arg), has been reported in 129,639 unrelated
controls of the gnomAD and EVS databases or in the 1000
Genomes Project; c.2531T>G (p.Leu844Arg) was reported
once in Latino (the variant’s frequency in all populations
is 0.00041%). Based on in silico analysis, all alterations are
predicted to be deleterious (SIFT) and probably or possibly
damaging (PolyPhen-2). Additionally, CADD classified all
variants as more likely to have deleterious effects
(range: 22.6 to 31). In contrast to results of in silico analysis,
suggesting a possible effect of two identified alterations
(c.2542G>A and c.2543G>A) on splicing through creation
of a novel exonic splice acceptor sequence, transcript
analysis and sequencing showed a minor effect on splicing
only for c.2542G>A in three individuals (UAB-R9493, UABR1474, and UAB-R0008), i.e., low levels of r.2410_2543del.
The other individuals with c.2542G>A screened with an
RNA-based approach (UAB-R3513 and UAB-R4476) in
whom no missplicing was observed also carried the nearby
benign variant c.2544G>A (p.Gly848¼) (rs17883704) with
both variants proven to reside in cis through next-generation sequencing. As missplicing was observed only in individuals carrying c.2542G>A in the absence of rs17883704
(Figure S4), rs17883704 is hypothesized to have a
modifying effect. All missense mutations, except for
c.2536G>C (p.Ala846Pro), were proven to be de novo in at
least one proband; a total of 26 probands with unaffected
parents were proven to have a de novo mutation, but formal
confirmation of paternity/maternity by identity testing was
pursued only for individuals tested in the Netherlands
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Figure 1. Spectrum of Missense Mutations Affecting NF1 Codons 844–848 in the Cohort of 129 Probands and 33 Relatives
Shown are 129 probands (A) and 33 relatives (B). Each number in circle corresponds with the total number of individuals heterozygous
for a specific mutation. The black dotted lines on the panels present the region 844–848. The figure was prepared using the ProteinPaint
application.44

(ROT-R02233, ROT-R22853, and ROT-R17435). Additionally, 7/12 missense mutations (c.2530C>T [p.Leu844Phe],
c.2533T>C [p.Cys845Arg], c.2536G>C [p.Ala846Pro],
c.2537C>A [p.Ala846Asp], c.2540T>C [p.Leu847Pro],
c.2542G>C [p.Gly848Arg], and c.2543G>A [p.Gly848Glu])
segregated with the phenotype (at least one individual per
family) in 23 affected first-degree relatives from 15 families
(Tables S1 and S2 and Figure S5). Finally, all missense mutations affecting amino acids 844–848 are located in a highly
conserved region of the CSRD (amino acids 543–909;
Figure S6). Besides cysteine at position 845 that is conserved
up to zebrafish, all remaining amino acids are evolutionarily conserved up to Drosophila melanogaster (Ala846 and
Gly848) and even to yeast IRA1 and/or IRA2 (Leu844 and
Leu847). In chimpanzee, rat, and mouse all amino acids
from 775 to 856 are fully evolutionarily conserved. None
of these variants has been functionally characterized.
Demographic and Clinical Characterization of the
Studied Cohort
A total of 162 individuals from 129 unrelated families
were enrolled in the study, including 37/129 (28.7%)
familial and 89/129 (69%) sporadic case subjects; 3/129
(2.3%) individuals had an unknown family history

(ROT-R13734, ROT-R89874, and CAR-R8012M6). Detailed
demographic and clinical descriptions of the individuals
included in the study are shown in Tables 1 and S1 and
Figure S5.
The complete phenotypic checklist forms were collected
from 151/162 individuals (93.2%). Of these, 125/151
(82.8%) fulfilled the NIH diagnostic criteria and 118/151
(78.2%) fulfilled the NIH diagnostic criteria if family history was excluded as a criterion. Among 26/151 individuals
who did not fulfill the NIH diagnostic criteria (with 20/26
being %8 years), multiple CALMs-only (>5) were present
in 16/26, <6 CALMs-only were present in 8/26, and 2/26
did not have any pigmentary manifestations but had
externally visible plexiform neurofibromas (UAB-R9135
and UG-R5831) (Table S5). CALMs-only (<6) were observed
mostly in individuals with a missense mutation at
codon 848 (5/8 with c.2542G>C [p.Gly848Arg], 1/8 with
c.2542G>A [p.Gly848Arg], 1/8 with c.2543G>A
[p.Gly848Glu], and 1/8 with c.2534G>A [p.Cys845Tyr]).
Among 102 individuals R9 years, more than 5 CALMs
and skinfold freckling were present in 79.8% (79/99) and
80% (76/95), respectively (Table 1). Both clinical features
were found in 71.6% (68/95) of case subjects. Out of 20
individuals R9 years with only few or absolute lack of
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CALMs (Table S1), 11 case subjects fulfilled the NIH diagnostic criteria based on presence of other clinical signs,
such as skinfold freckles, Lisch nodules, neurofibromas,
and/or osseous lesions (UG-R0781, UAB-R3618-M,
MIL-R192/982-F, UAB-R4476, MIL-R999/399, MIL-R999/
399-M, ROT-R95424, UG-R923-S, UAB-R3237, MANR95417G, and MAN-R95417G-C). Among these individuals, 8/11 (72.7%) carried a missense mutation at
codon 848. Lisch nodules were reported less frequently
(42/98 all ages, but in 34/60 R9 years).
Cutaneous and subcutaneous neurofibromas were found
in 68.1% (47/69 R19 years) and 50.8% (33/65 R19 years)
of the case subjects, respectively. Thirty adults had both
types of tumors (30/64 R19 years, 46.9%). Ten individuals
R17 years had >100 cutaneous and/or subcutaneous
nodules, including a 47-year-old man previously
reported45 with >1,400 neurofibromas (individual counts
of externally visible neurofibromas; BRA-R38) and a
17-year-old woman (ROT-R1CMUL) with >500 cutaneous
neurofibromas, >100 subcutaneous neurofibromas, and
>100 intradermal neurofibromas. Nine out of ten
individuals with a very high number of neurofibromas
carried a missense mutation at codon 847: c.2540T>G
(p.Leu847Arg) (2/9) or c.2540T>C (p.Leu847Pro) (7/9,
including two individuals with metastasized MPNSTs). In
16 case subjects with ‘‘several’’ neurofibromas, a more precise estimated number was not reported. Eight individuals
(UAB-R5776, UAB-R3618, UAB-R4624, UAB-R7447,
UAB-R1002, UAB-R1037-M, UAB-R3237, PAD-R500-C1)
were reported to have a single cutaneous or subcutaneous
nodule (none histopathologically confirmed); these individuals were considered as ‘‘negative for the criterion of
neurofibromas’’ as R2 cutaneous/subcutaneous neurofibromas are required according to the NIH clinical criteria.
45% of the individuals R9 years had known plexiform
neurofibromas (41/92 R9 years; 47/143 all ages), including
externally visible (n ¼ 36) and internal (n ¼ 5) tumors. For
six case subjects, the information was not provided
whether plexiform neurofibromas were identified clinically
or by MRI. Among all individuals with plexiform neurofibromas, 31/47 presented with one plexiform tumor and
16/47 with R2 plexiform neurofibromas. Plexiform tumors
were found in the head, face, and neck area (35.7%, 25/70),
limbs (34.3%, 24/70), trunk (17.1%, 12/70), back (n ¼ 3),
abdomen (n ¼ 3), pelvis (n ¼ 2), and chest (n ¼ 1).
Symptomatic spinal neurofibromas visible by MRI were
found in 15.2% of individuals (12/79 R9 years; 13/127
all ages). Forty asymptomatic individuals received MRI
screening, leading to the identification of another seven
case subjects with spinal tumors (Table S6). Approximately
one-third of the individuals with spinal tumors (6/20) had
fewer than 6 CALMs and no skinfold freckling, whereas in
60% (12/20) plexiform neurofibromas were observed (with
11/12 being externally visible).
Symptomatic OPGs, confirmed by MRI imaging, were
found in 11/104 of individuals older than 5 years
(10.6%), whereas asymptomatic OPGs were present in

16/52 additional individuals who underwent MRI examination (30.8% R5 years). In 19 of 27 symptomatic and
asymptomatic OPGs, the detailed information about the
tumor’s location was collected, involving optic nerves
(2 symptomatic OPGs and 7 asymptomatic OPGs), chiasm
(1 symptomatic OPG and 1 asymptomatic OPG), or both
locations (6 symptomatic OPGs and 2 asymptomatic
OPGs). Three children were diagnosed with a symptomatic
OPG (PAD-R300) or asymptomatic OPGs (UAB-R3714 and
UAB-R3513) before age 4 years (Table S7).
Skeletal abnormalities were frequently reported (48/
144 all ages) and included scoliosis (27/144 all ages,
but 20/64 R19 years) and pectus anomalies (10/144 all
ages: pectus carinatum 6/10 and excavatum 4/10). In
addition, long bone dysplasia (n ¼ 4), pseudarthrosis
(n ¼ 2), tibial dysplasia (n ¼ 1), bone cysts (n ¼ 2),
sphenoid wing dysplasia (n ¼ 2), ulnar aplasia, likely
representing the severe end of ulnar pseudarthrosis
with bone resorption and absence of ulnar bone
(n ¼ 1), dural ectasia (n ¼ 1), 4th lumbar vertebrae
fragmentation (n ¼ 1), bowed long bones (n ¼ 1),
clinodactyly (n ¼ 1), postaxial polydactyly (n ¼ 1), and
cherubism (n ¼ 1) were observed in the studied group.
Noonan syndrome features were observed in 10/134
(7.5%) individuals. One previously reported individual
(UAB-R624) with a family history of PTPN11-positive
(MIM: 176876) Noonan syndrome (MIM: 163950) had a
severe phenotype of pulmonic stenosis and aortic coarctation, dysmorphic features (high forehead, hypertelorism,
downslanting palpebral fissures, short neck with a low
posterior hair line), short stature, pectus carinatum, >5
CALMs, axillary and inguinal freckling, plexiform and
cutaneous neurofibromas, and symptomatic OPG with
signs of hydrocephalus.46 Besides the familial PTPN11
c.1529A>G (p.Gln510Arg) inherited from the individual’s
father, the NF1 missense mutation c.2531T>G
(p.Leu844Arg) was found de novo in the proband
(Figure S5). In other individuals with Noonan syndrome
features (UAB-R2696, UAB-R5001, UAB-R3725, and UABR4676) no pathogenic or likely pathogenic variants in
Noonan-related disorders genes (PTPN11 [MIM:176876],
SPRED1 [MIM:609291], BRAF [MIM: 164757], CBL [MIM:
165360], HRAS [MIM: 190020], KRAS [MIM: 190070],
MAP2K1 [MIM: 176872], MAP2K2 [MIM: 601263], NRAS
[MIM: 164790], RAF1 [MIM: 164760], SHOC2 [MIM:
602775], SOS1 [MIM: 182530], RIT1 [MIM: 609591],
RASA2 [MIM: 601589], and SOS2 [MIM: 601247]) were
identified. Cardiovascular abnormalities observed in the
studied group included hypertension (n ¼ 7, one related
to renal artery stenosis), pulmonic stenosis (n ¼ 2), mitral
valve stenosis, atrial septal defect, ventricular septal defect,
Moyamoya disease, pericarditis carcinomatosa, mitral
valve insufficiency, mild pulmonic insufficiency, and
hypertrophic cardiomyopathy (each observed in a single
individual). Short stature (PC % 3) and macrocephaly
(PC R 98) were found in 15/91 (16.5%) and 36/98
(36.7%), respectively. Of the 138 case subjects with
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provided developmental data, 56 individuals had
abnormal development presenting with at least one of
the following forms of cognitive impairment and/or
learning difficulties: learning disabilities (n ¼ 43), developmental delay (n ¼ 30), speech delay (n ¼ 8), ADD (n ¼ 8),
ADHD (n ¼ 10), motor delay (n ¼ 5), autism spectrum (n ¼
2), or Asperger syndrome (n ¼ 1). Seven individuals had
significant global developmental delay with/without
speech delay, learning difficulties, and/or AD(H)D,
including one with a full scale intelligence quotient
(FSIQ) score 59. Additionally, three individuals were
reported to have frequent migraine headaches and two
had epilepsy and/or psychiatric problems.
For 139/162 individuals, data on the presence or absence
of tumors other than neurofibromas and OPGs was available. 13 of 139 (9.4%) individuals were diagnosed with
malignant neoplasms (Table S8), including embryonal
rhabdomyosarcoma (3/13), MPNST (7/13, including one
woman with MPNST and BRCA1/2-negative breast cancer),
colon cancer (1/13), medullary thyroid carcinoma (1/13),
and juvenile myelomonocytic leukemia (JMML) (1/13).
Individuals R14 years old with c.2540T>C (p.Leu847Pro)
had a higher number of malignant neoplasms compared to
individuals carrying other missense mutations in the studied region (p ¼ 0.0448; Table S9). Moreover, this mutation
was present in most case subjects with MPNST (5/7),
except for one each carrying c.2543G>A (p.Gly848Glu)
or c.2530C>T (p.Leu844Phe). Four of seven individuals
with MPNST died before age 30 years (Table S8). Hypothalamic glioma (n ¼ 1), lipoma (n ¼ 1), cerebral tumors
(n ¼ 3), non-ossifying fibroma (n ¼ 2), and odontogenic
fibroma (n ¼ 1) were also reported.
The frequency of clinical features in individuals
heterozygous for missense mutations affecting one of five
neighboring codons 844–848 is presented in Table 2. A
lower number of CALMs, freckling, and cutaneous neurofibromas was observed in case subjects with missense
mutations at codon 848 (all p < 0.0001; Table S9); however, these individuals had a higher prevalence of symptomatic spinal neurofibromas (p ¼ 0.0012; Table S9).
Taken together, a severe phenotype, including at least
one of the following features (plexiform and/or symptomatic spinal neurofibromas, symptomatic OPGs, malignant
neoplasm, or osseous lesions) was observed in 75% of adult
NF1-affected individuals (56/75 R19 years; Table 2).
Comparison of Clinical Features Observed in the Studied
Cohort with Individuals Heterozygous for p.Arg1809
and p.Met992del Mutations and Cohort of Individuals
with ‘‘Classic’’ NF1 Phenotype
Comparison of clinical features of the studied group with
the NF1 p.Arg1809 and p.Met992del cohorts as well as previously described large-scale cohorts of individuals with
‘‘classic’’ NF1 is shown in Table 3. The complete list of
adjusted p values with FDRs at 0.05 and 0.01 after B-H
correction for multiple testing is presented in Table S10.
All p values % 0.0125 and p values % 0.0012 remained

statistically significant after applying the B-H correction
at FDRs of 0.05 and 0.01, respectively.
In the current study, we observed a significantly
higher number of major external plexiform neurofibromas compared with the NF1 p.Arg1809 and the NF1
p.Met992del cohorts, as well as classic NF1-affected population (all p < 0.0001; statistically significant after B-H
correction at FDR of 0.01). Importantly, while none of
the individuals carrying the p.Arg1809 and p.Met992del
had external plexiform, cutaneous, and/or subcutaneous
neurofibromas, 71% of the individuals R19 years with
a missense mutation affecting codons 844–848 had cutaneous and/or subcutaneous neurofibromas (p < 0.0001;
statistically significant after B-H correction at FDR of
0.01) and 39% of the individuals R9 years had
externally visible plexiform neurofibromas (p < 0.0001;
statistically significant after B-H correction at FDR of
0.01). Compared with p.Arg1809, p.Met992del, and
classic NF1-affected cohorts, at least 5-fold greater prevalence of symptomatic spinal neurofibromas was reported
in the studied group (0%–2.1% versus 10.2%) which was
statistically significant at FDR of 0.01 for the general
NF1-affected population (p < 0.0001) and at FDR of
0.05 for the p.Arg1809 cohort (p ¼ 0.0022).
Symptomatic and asymptomatic OPGs were more
frequent compared to individuals with p.Arg1809,
p.Met992del, and classic NF1, with symptomatic and
asymptomatic OPGs statistically increased after B-H correction at FDR of 0.05 in the 844–848 cohort compared to the
classic NF1-affected cohorts (p ¼ 0.0125 and p ¼ 0.0043,
respectively) and at FDR of 0.01 compared with the
p.Arg1809 cohort (p ¼ 0.0002 and p < 0.0001, respectively). The overall prevalence of malignant neoplasms,
other than neurofibromas and OPGs, was also higher in
the studied group compared to a large cohort of classic
NF1-affected individuals (9.4% versus 3.4%; p ¼ 0.0061,
statistically significant at FDR of 0.05 after B-H correction).
Additionally, the aa 844–848 cohort had a significantly
increased frequency of skeletal abnormalities compared
to individuals with p.Arg1809 and classic NF1 phenotypes
(both statistically significant after B-H correction at FDR of
0.05), regardless of the age. Scoliosis was reported more
frequently compared with p.Arg1809 individuals (31.3%
versus 12.5% in R 19 years), but this difference was not
statistically significant after B-H correction.
The prevalence of CALMs was lower than in p.Arg1809
and p.Met992del cohorts (both significant at FDR of 0.05
after B-H correction), while skinfold freckles occurred
more commonly in classic NF1-affected cohorts than in
the studied group (significant at FDR of 0.01 after B-H
correction). Noonan syndrome features were significantly
less frequent in the studied group compared to individuals
with p.Arg1809 (significant at FDR of 0.01 after B-H correction). In line with this finding, pulmonic stenosis was very
rarely observed in the cohort (1.8% versus 10.6% in the
p.Arg1809 cohort; significant at FDR of 0.05 after B-H
correction). All cohorts, except for the p.Met992del, shared
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a similar frequency of cognitive impairment and/or
learning difficulties (45%).

Discussion
We present 162 individuals heterozygous for a constitutional NF1 missense mutation in one of five neighboring
codons 844–848 who have a high prevalence of a severe
NF1 phenotype, including plexiform and/or symptomatic
spinal neurofibromas, symptomatic OPGs, and other
malignant neoplasms, as well as bone abnormalities.
The frequency of the cluster of these mutations is 0.8%
(67/8,400) in unrelated NF1 mutation-positive individuals
from the UAB cohort, second only to the p.Arg1809
(1.2%) among the missense variants.
One of the most severe complications in NF1-affected
individuals are clinically apparent plexiform neurofibromas affecting 15%–30% of the NF1-affected general
population.7,34,47–50 In this study, externally visible plexiform neurofibromas were found in 39% of individuals
R9 years, therefore significantly higher compared with
p.Arg1809 and p.Met992del and classic NF1-affected
cohorts (significant at FDR of 0.01 after B-H correction;
Tables 3 and S10). Individuals in this study did not
undergo whole-body MRI; therefore, the frequency
provided here is a likely underestimate, as internal asymptomatic plexiform neurofibromas were not accounted for.
As plexiform neurofibromas have been suggested to be
associated with a higher lifetime risk for the development
of MPNSTs,50–53 the finding of MPNSTs in 5% (7/139) of
the affected in our cohort, which is twice as high as
reported by Huson et al. in the South-East Wales
cohort,28,29 is in line with expectations.
Approximately 24%–40% of NF1-affected individuals
develop spinal neurofibromas,35,39,52 but they are most
often asymptomatic and not detectable by physical examination. The estimated prevalence of symptomatic spinal
neurofibromas in the general NF1-affected population is
less than 2%.7,34,35 In the current study, a high number
of individuals with symptomatic spinal neurofibromas
was reported, compared to the classic NF1-affected cohorts
(statistically significant at FDR of 0.01 after B-H correction): 13/127 (10.2%) for all ages and 12/79 (15.2%) for
R9 years. Kluwe et al. suggested that spinal neurofibromas
cause symptoms mainly in older case subjects (mean age
32.8 years),18 but 4 of 13 symptomatic individuals in our
cohort were below age 18 (range: 7–17 years). In 40 individuals who underwent MRI examination, an additional
seven case subjects with asymptomatic spinal neurofibromas were found. Among all affected individuals, five
belonged to two previously reported multi-generation
families (UG-R923 and MAN-R95417G) where the spinal
tumors segregated within the family.16,21 For two relatives
of these probands, the spinal neurofibromas were recognized only after MRI, although the tumor burden was
extensive. None of the individuals had >5 CALMs,

including 2/5 who had <6 CALMs and 3/5 had none.
This rare form of NF1 is called familial spinal neurofibromatosis (FSNF).
Plexiform and spinal tumors as well as subcutaneous
neurofibromas are associated with a severe NF1 phenotype
and may result in significant morbidity in children and
adults.54,55 OPGs, the most common brain tumors in children, are another complication in the general NF1-affected
population.56 The overall prevalence of OPGs in the
NF1-affected population is 11%–20%,39,50,57 but only
30% of these individuals have clinically symptomatic
OPGs and present with impaired visual acuity, visual field
loss, abnormal color vision, squint, proptosis, and/or
hypothalamic dysfunction.49 Most symptomatic OPGs
are diagnosed before age 7 years57 with the mean age of
5 years.58 In the studied group, symptomatic OPGs were
found in 11/104 (10.6%) of individuals R5 years, which
is more frequent compared with p.Arg1809 and
p.Met992del cohorts (none of the individuals had OPGs)
and with classic NF1-affected population (3.9%); however,
after applying the B-H correction, only the result of
comparison with p.Arg1809 cohort and the general NF1affected population remained statistically significant at
FDR of 0.05 (Tables 3 and S10). Furthermore, there was a
higher prevalence of asymptomatic OPGs in 16/52
(30.8%) individuals R5 years who underwent MRI examination (statistically significant at FDR of 0.01).
Individuals with NF1 are at higher risk to develop specific malignancies compared with the general population,
significantly increasing mortality.59,60 Besides the highgrade gliomas, the most common malignancies in
NF1-affected children are rhabdomyosarcomas, JMML,
and neuroblastomas, but accurate estimates on prevalence
are not available due to the rarity of these tumors.61,62
Based on the data provided by Sung et al. and Crucis
et al.,63,64 the prevalence of rhabdomyosarcomas in children with NF1 is estimated at 0.4%–0.5%, while Chang
and Shannon reported that the individual risk of JMML
in NF1 is 0.04%.65 In the studied group, three NF1affected children younger than 5 years developed embryonal rhabdomyosarcomas, including one individual, now
>26 years, who survived both a rhabdomyosarcoma and
astrocytoma grade II, diagnosed at the age 2 and 15 years,
respectively. Furthermore, one 5-year-old girl (out of 50
children %8 years) presented with <6 CALMs and JMML.
This girl was heterozygous for two pathogenic NF1 mutations in the blood, c.2542G>A (p.Gly848Arg) as well as
c.1246C>T (p.Arg416*), with p.Gly848Arg being the first
hit given the absence of p.Arg416* in buccal swabs, indicating somatic mosaicism for p.Arg416*. A UK population-based hospital admission and death certificate study
found that individuals with NF1 have, after excluding
the well-established risks of nervous systems tumors, a
2.7-fold increased risk of developing cancers of the esophagus, stomach, colon, liver, lung, bone, thyroid, malignant
melanoma, non-Hodgkin lymphoma, chronic myeloid
leukemia, breast, and ovary.66 In the current study, we
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noted recurrent malignant tumors, such as MPNSTs
(7/139; 5%) (Tables S1 and S8). Among these individuals,
one 44-year-old woman previously described with the
missense mutation c.2540T>C (p.Leu847Pro) had MPNST,
BRCA1/2-negative (MIM: 113705 and 600185) breast cancer as well as a high number of cutaneous neurofibromas
(>100).67 In addition, one individual developed a medullary thyroid carcinoma and three first-degree relatives of
a Belgian proband with c.2540T>C (p.Leu847Pro) died
from malignancies (a metastasized colon adenocarcinoma
and two MPNSTs, both deceased before age 26). Taken
together, the overall prevalence of malignant neoplasms
in the studied group was substantially higher than in the
published datasets of the general NF1-affected population
(significant at FDR of 0.05 after B-H correction; Tables 3
and S10). Furthermore, specifically mutation p.Leu847Pro
seems to confer a high predisposition to develop malignant tumors compared to other missense variants reported
in this study (p < 0.0448; Table S9), although the CADD
score of this variant is not the highest among the studied
region (only 26.1; Table S2). Given the predominance of
the p.Leu847Pro mutations in the studied cohort (70/162
individuals), larger datasets are required to further refine
the increased tumor risk associated with the other
mutations within the studied region.
Skeletal abnormalities, including long bone dysplasia
with or without pseudarthrosis, scoliosis, sphenoid wing
dysplasia, bone cysts, including cherubism, non-ossifying
fibromas and osseous giant cell lesions, hand anomalies,
anterior chest wall anomalies, and short stature, can
lead to serious clinical consequences and significant
morbidity.68 We observed a clear overall increase in the
number of skeletal anomalies compared with p.Arg1809
(FDR of 0.05 after B-H correction) and the general NF1-affected population (FDR of 0.01 after B-H correction). As
many as 33.3% of the NF1-affected individuals (48/144)
presented with one or more osseous lesion, scoliosis
(n ¼ 27), and pectus anomalies (n ¼ 10) being most
frequent (18.8% and 6.9%, respectively). The overall frequency would be higher if individuals with short stature
(40.3%; 58/144) are included. Rarely reported complications possibly associated with NF1 status included cherubism, chronic arthritis of multiple joints with elbow
contractures, clinodactyly of the 3th–5th toes, postaxial
polydactyly, and ulnar aplasia, likely representing the severe end of ulnar pseudarthrosis with bone resorption
and absence of the ulnar bone. Interestingly, the latter
has been reported only in two NF1-affected case subjects.69 Mild to moderate scoliosis was reported in only
18% of NF1-positive individuals with bilateral neurofibromas of all spinal roots;17 however, in our study we
observed co-occurrence of scoliosis and spinal tumors in
45% (9/20) of individuals with confirmed symptomatic
or asymptomatic spinal neurofibromas (not necessarily
affecting all dorsal roots) (Table S6). An additional 11 individuals had scoliosis without evidence of spinal neurofibromas by MRI (Table S1).

Cohorts of individuals with NF1 missense mutations
affecting codons 844–848 and classic NF1-affected population shared a similar frequency for short stature and
macrocephaly. Noonan syndrome features were rarely
observed in the studied group compared with the
p.Arg1809 cohort (significant at FDR of 0.01 after B-H
correction). In line with previous studies,7,34,39,70 intellectual disability, developmental delay, and/or learning
difficulties were frequently observed in the current
study (40.6%).
Among the 129 unrelated probands with a missense
mutation affecting codons 844–848, p.Leu847Pro and
p.Gly848Arg are the most recurrent variants, found in 58
and 14 unrelated individuals, respectively (Table S2 and
Figure 1). Both alterations are associated with a severe
NF1 phenotype, including a high prevalence of plexiform
neurofibromas and skeletal abnormalities, compared to the
general NF1-affected population. However, missense mutations at p.Gly848 predispose with a greater frequency to
symptomatic or asymptomatic spinal tumors, which
were found in 70% of probands carrying the p.Gly848Arg
or p.Gly848Glu mutations (9/13 R9 years, but in 9/10 R9
years who received MRI screening), which is slightly
higher than in individuals presenting with a severe phenotype caused by a total NF1 deletion (8/13 R9 years).71
Several of the severely affected individuals with a missense
mutation at p.Gly848 had only few or no pigmentary skin
findings. So far, 100 case subjects have been reported
with the true ‘‘spinal NF’’ phenotype17 and these individuals more frequently carry a splice site or missense mutation spread over the entire NF1 coding region.18–20 So far,
no single mutation has been correlated with this severe
clinical presentation. We provide the specific genotypephenotype association between a particular NF1 mutation
and the spinal phenotype. Individuals with missense
mutations at p.Gly848 appear to constitute a distinct
group of NF1-affected individuals with a high prevalence
of symptomatic spinal neurofibromas and a clear decrease
of pigmentary manifestations (CALMs and skinfold
freckles) as well as cutaneous neurofibromas (Tables 2
and S9). Because of the limited number of individuals
R9 years old with the missense mutations at codons
844–846, it is still difficult to establish a genotype-phenotype correlation among these cohorts; however, so far
these variants also seem to be associated with a severe
phenotype, including a high prevalence of plexiform
neurofibromas in the p.Cys845 and p.Ala846 cohorts
(57.1% and 66.7%, respectively) and OPGs in p.Leu844
cohort (24% for both symptomatic and asymptomatic
OPGs in R5 years). At this moment, it cannot be excluded
that two specific genotype-phenotype correlations exist
within this small region of NF1 with the NF1 codon 847
associated with an increased risk for malignant neoplasia
and the NF1 codon 848 associated with a high prevalence
of symptomatic spinal neurofibromas. The current study,
however, intended to show that the whole region of
844–848 codons stood out due to its high frequency of
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variants compared with the neighboring codons, indicating functional importance. In addition, the cluster of
missense mutations here described, although located
outside the GRD important for RAS regulation, is clearly
associated with a severe phenotype, not reported so far
in literature. As the current study necessarily still
underestimates the internal tumor burden, as systematic
whole-body imaging was not performed, close clinical
management seems warranted for individuals presenting
with a missense variant affecting aa 844–848.
As NF1 is known for its variable expressivity and age dependency, it is challenging to establish genotype-phenotype correlations. Although we performed a comparative
analysis on a large well-described cohort using a standardized phenotypic data collection form, one limitation of the
study is that clinical information was collected by physicians from different referral centers, although all were
NF1 specialists. Data in this and the previously reported
p.Arg1809 cohort were ‘‘double-checked’’ through verification of the originally submitted phenotypic checklist
forms and subsequent update of the clinical notes, so
data should be highly accurate.
Clinical variability, both inter- and intrafamilial, has
been widely reported in the past two decades.72–74
Although significant progress has been made over the
last 20 years, the mechanisms underlying this phenotypic
heterogeneity only gradually start to be unraveled. The
factors contributing to the phenotypic variability include
(1) age dependency of some of the NF1 features,29,75,76
(2) timing, cell of origin, and number of second hits in
specific cells, resulting in presence and number of CALMs,
freckling, tibial dysplasia, neurofibromas, and other
tumors,77 (3) post-zygotic mosaicism for the first NF1 hit
in mosaic individuals,77 (4) the enormous NF1 allelic heterogeneity,78 (5) occasional presence of two different NF1
pathogenic variants segregating within a family (see MADR9.232; Table S1 and Figure S5) or the occurrence of two
independent mutations, one in NF1 and the other in a
different gene, within an individual (see UAB-R624
with the NF1/PTPN11 mutations and UF-R1 with the
NF1/KIT mutations; Table S1), (6) modifying genes,79
and (7) environmental factors (e.g., number of pregnancies).80 To date, two studies have identified potential
modifying genes, unlinked to the NF1 locus, associated
with the severity of NF1 presentation.81,82 Pasmant et al.
demonstrated that a high number of plexiform neurofibromas has been significantly associated with allele T
of SNP rs2151280 of ANRIL (MIM: 613149).81 Pemov
et al. reported a correlation of two common SNPs
(rs4660761 and rs7161), located between DPH2 (MIM:
603456) and ATP6V0B (MIM: 603717), as well as of SNP
rs1800934 in MSH6 (MIM: 600678) with the number of
CALMs.82 Further studies are needed to confirm these
findings.
Missense mutations affecting NF1 codons 844–848
described in this study are clearly pathogenic and individuals with these missense mutations have a statistically

higher risk of developing spinal neurofibromas, plexiform
neurofibromas, and OPGs. Functional studies in mutant
mice harboring the missense mutation c.2542G>C
(p.Gly848Arg) did not recapitulate this human phenotype, as neither optic pathway gliomas nor plexiform
neurofibromas developed.22,23 Western blot analysis
showed that c.2542G>C (p.Gly848Arg) resulted in 38%–
50% reduction of neurofibromin levels.22,23 These mutations reside outside the GRD (amino acids 1,217–1,511),
known to have tumor-suppressor activity through
downregulation of members of the Ras family of small
GTP-binding proteins. Although NF1 was cloned in 1990,
the cellular functions performed by this huge 2,818-amino
acid multi-domain protein are still incompletely understood. The cluster of recurrent missense mutations
involving aa 844–848 described in the current study are
located within the CSRD (amino acids 543–909), located
N-terminal to the GRD. The CSRD domain, originally
described by Fahsold et al.,83 is likely functionally important, which is further implied by the presence of multiple
missense variants in this segment of the gene in NF1affected individuals. The 3D structure of this region has
not been resolved and its precise functions and interactors
have not been described. Ras GAP activity is enhanced
through phosphorylation by Protein Kinase Ca of serine
and threonine residues within this domain.84 Based on
the 2D modeling of the CSRD using PredictProtein
server,85 the region 831–847 might form the C-part of a helix and be buried in the protein. Missense mutations
affecting codons 844–848, especially those substituting
smaller hydrophobic amino acids to large ones, may result
in breaking of the helix and exposure of the buried protein
domain, consequently affecting the function of the protein. No functional studies confirming the aforementioned
bioinformatics analysis have been performed, however. In
any case, missense mutations in this region seem to act
through a loss-of-function mechanism and not gain-offunction or dominant-negative, at least in melanocytes
and JMML. Indeed, the c.2540T>C (p.Leu847Pro) was
observed as a ‘‘second hit’’ in one CALM, biopsied from a
13.5-year-old girl with >5 CALMs and skinfold freckling
carrying the NF1 constitutional mutation c.55471G>A
(Table S11), confirming that two hits are required to cause
a phenotypic effect. Additionally, we reported a 5-year-old
girl with JMML (UAB-R9493; Table S1) who carried two
pathogenic NF1 mutations in the blood: c.2542G>A
(p.Gly848Arg) as a ‘‘first hit’’ mutation and c.1246C>T
(p.Arg416*) as a ‘‘second hit.’’ There is a need to improve
our understanding of the physiological functions of neurofibromin and to determine how each domain regulates the
function of this protein.
Six amino acids in the region aa 804–950 are evolutionarily conserved down to yeast (IRA1 and IRA2), Leu844,
Gly849, Leu852, Glu924, Leu933, and Phe934
(Figure S6) and would therefore be expected to be of
particular functional importance.86 Only Leu844 and
Leu933 have, however, been observed in NF1-affected
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individuals to predispose to recurrent missense mutations
(HGMD, LOVD, ClinVar, and our cohort). The tumorigenic potential of aa 844 is further highlighted by identification of somatic mutations in the COSMIC database:
one glioma with c.2531T>C (p.Leu844Pro), one glioma
and four malignant melanomas with c.2530C>T
(p.Leu844Phe).
Palindromic structures belong to the non-B DNA structures and are often the site of replication errors resulting
in substitutions.87 The NF1 missense mutation hotspot
(aa 844–848) is located in the highly conserved amino
acid region, suggesting that it is functionally important.
The genomic sequence encoding the human NF1 aa
845–853 is a part of two palindromic structures
(Figure S7); therefore the high rate of recurrent missense
mutations affecting Leu847 and Gly848 may partially be
due these being both located in the loop of the
palindrome. In NF1 exon 21 [16], other palindromic
nucleotide sequences, specifying the amino acid residues
aa 828–832, aa 865–868, aa 908–911, and aa 933–937 are
observed, resulting in four additional stem-loop structures. However, these structures do not predispose to
recurrent missense mutations as none were found either
in the UAB, HGMD, or LOVD cohort, except for
c.2798T>C (p.Leu933Pro), whose location does not
include the loop of the palindrome. The complex
interplay between functional significance and genomic
architecture needs to be considered when analyzing the
recurrence of mutations.
Although only a few clear genotype-phenotype correlations have been so far reported,11–14 the data presented
here show that additional clinically relevant NF1 genotype-phenotype correlations exist. A renewed interest in
such studies is needed to come to a timely unfolding of
additional correlations, as so far only the surface has
been scratched. This will require close collaboration between NF1 clinicians and molecular geneticists. The lack
of discovery of more specific genotype-phenotype
correlations may be partly due to the methodological
approach, including lumping mutations in large categories (truncating versus microdeletion, splice, missense
mutations).88,89
Identification
of
mutation-specific
genotype-phenotype correlations depends on the dataset
size with a large number of individuals, preferentially
postpubertal, carrying the same non-truncating constitutional mutation, with the associated phenotype recorded
in a standardized way. As there are only a limited number
of truly recurrent non-truncating mutations, prioritization on individuals carrying such recurrent mutations is
indicated. Although each of the recurrent mutation
affects only a small percentage of NF1-affected individuals
(3%–8% with the microdeletion type I, 0.8% with
p.Met992del, 1.2% with the p.Arg1809 missense mutation, and 0.8% for the cluster of missense mutations
affecting codons 844–848), together they may affect
counseling and surveillance in a significant fraction of
the NF1-affected population.

In conclusion, the present findings indicate that
missense mutations affecting one of five neighboring
codons 844–848 located outside the GAP-related domain
are an important risk factor for a severe phenotype in
NF1-affected individuals. We report that these individuals
have a high prevalence of plexiform and/or spinal neurofibromas, symptomatic and asymptomatic OPGs, malignant neoplasms, and skeletal abnormalities. A severe
phenotype was observed in 75% of adult NF1-affected
individuals with these mutations, clearly demonstrating
that missense mutations outside the GRD can be
associated with a severe clinical presentation. The current
study identified a genotype-phenotype correlation in this
region that may be valuable in the management and
genetic counseling of a significant number of NF1-affected
individuals. These data suggest that there is a potential
need for increased disease surveillance in individuals
with these mutations enabling genotype-driven personalized medicine.
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S., Högel, J., Spöri, H., Cooper, D.N., and Kehrer-Sawatzki, H.
(2010). Clinical characterisation of 29 neurofibromatosis
type-1 patients with molecularly ascertained 1.4 Mb type-1
NF1 deletions. J. Med. Genet. 47, 623–630.
Easton, D.F., Ponder, M.A., Huson, S.M., and Ponder, B.A.
(1993). An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.
Am. J. Hum. Genet. 53, 305–313.
Szudek, J., Joe, H., and Friedman, J.M. (2002). Analysis of intrafamilial phenotypic variation in neurofibromatosis 1
(NF1). Genet. Epidemiol. 23, 150–164.
Sabbagh, A., Pasmant, E., Laurendeau, I., Parfait, B., Barbarot,
S., Guillot, B., Combemale, P., Ferkal, S., Vidaud, M., Aubourg,
P., et al.; members of the NF France Network (2009). Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum. Mol. Genet. 18, 2768–2778.
DeBella, K., Szudek, J., and Friedman, J.M. (2000). Use of the
national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105, 608–614.
Williams, V.C., Lucas, J., Babcock, M.A., Gutmann, D.H., Korf,
B., and Maria, B.L. (2009). Neurofibromatosis type 1 revisited.
Pediatrics 123, 124–133.
Messiaen, L., and Xie, J. (2012). NF1 germline and somatic
mosaicism. In Neurofibromatosis Type 1. Molecular and
Cellular Biology, M. Upadhyaya and D.N. Cooper, eds.
(Springer-Verlag Berlin Heidelberg), pp. 151–172.
Messiaen, L.M., and Wimmer, K. (2008). NF1 mutational spectrum. In Neurofibromatoses, D. Kaufmann, ed. (Monogr.
Hum. Genet. Basel: Karger), pp. 63–77.
Pasmant, E., Vidaud, D., and Wolkenstein, P. (2012). Modifier
genes in NF1. In Neurofibromatosis Type 1. Molecular and
Cellular Biology, M. Upadhyaya and D.N. Cooper, eds.
(Springer-Verlag Berlin Heidelberg), pp. 269–285.
Terry, A.R., Barker, F.G., 2nd, Leffert, L., Bateman, B.T., Souter,
I., and Plotkin, S.R. (2013). Neurofibromatosis type 1 and
pregnancy complications: a population-based study. Am. J.
Obstet. Gynecol. 209, 46.e1–46.e8.
Pasmant, E., Sabbagh, A., Vidaud, M., and Bièche, I. (2011).
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Kücükceylan, N., Abdel-Nour, M., Gewies, A., Peters, H., Kaufmann, D., et al. (2000). Minor lesion mutational spectrum of
the entire NF1 gene does not explain its high mutability but
points to a functional domain upstream of the GAP-related
domain. Am. J. Hum. Genet. 66, 790–818.
Mangoura, D., Sun, Y., Li, C., Singh, D., Gutmann, D.H., Flores,
A., Ahmed, M., and Vallianatos, G. (2006). Phosphorylation of
neurofibromin by PKC is a possible molecular switch in EGF
receptor signaling in neural cells. Oncogene 25, 735–745.
Rost, B., Yachdav, G., and Liu, J. (2004). The PredictProtein
server. Nucleic Acids Res. 32, W321-6.

86. Ng, P.C., and Henikoff, S. (2001). Predicting deleterious amino
acid substitutions. Genome Res. 11, 863–874.
87. Kamat, M.A., Bacolla, A., Cooper, D.N., and Chuzhanova, N.
(2016). A role for non-B DNA forming sequences in mediating
microlesions causing human inherited disease. Hum. Mutat.
37, 65–73.
88. Sabbagh, A., Pasmant, E., Imbard, A., Luscan, A., Soares, M.,
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